| 1 |
NCT02030613 |
Completed |
Effective Dose of Etanercept in Patients Treated for Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Not Applicable |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Etanercept concentration-time courses
- Wallace criteria
- anti-etanercept antibodies levels
- (and 3 more...)
|
126 |
All |
4 Years to 17 Years (Child) |
NCT02030613 |
P111102 |
Etaplus |
October 1, 2013 |
February 28, 2017 |
March 30, 2017 |
January 8, 2014 |
July 5, 2017 |
|
- Hospital Necker
Paris, France
|
| 2 |
NCT02218580 |
Recruiting |
Massage Therapy in Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
- Other: Massage therapy
- Other: Standard care
|
Interventional |
Not Applicable |
- McGill University Health Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recruitment rate
- Retention rate
- Program adherence
- (and 11 more...)
|
30 |
All |
5 Years to 17 Years (Child) |
NCT02218580 |
CRA (CIORA grant #4) |
|
May 2015 |
January 2019 |
January 2019 |
August 18, 2014 |
March 30, 2018 |
|
- Montreal Children's Hospital - Glen site
Montreal, Quebec, Canada
|
| 3 |
NCT02977416 |
Recruiting |
Oxidation Rates of the Different Substrates During Exercise in Children and Adolescents With Juvenile Idiopathic Arthritis. Case-control Study and Cases Treated / Cases Not Treated With Anti-TNFα |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Not Applicable |
- University Hospital, Clermont-Ferrand
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
|
- Percentage variation of the maximal fat oxidative rate during an exercise between JIA and healthy children. Timing:
- Percentage variation of substrates oxidative crossing point during an exercise.
- Description of the contribution of energy systems during supra-maximal physical exercise
|
66 |
All |
8 Years to 18 Years (Child, Adult) |
NCT02977416 |
CHU-0295
2016-A01262-49 |
OSE-JIA |
November 2016 |
May 2020 |
September 2020 |
November 30, 2016 |
December 5, 2016 |
|
- CHU Clermon-Ferrand
Clermont-Ferrand, France
|
| 4 |
NCT01399281 |
Recruiting |
Pharmacovigilance in Juvenile Idiopathic Arthritis Patients Treated With Biologic Agents and/or Methotrexate |
- Juvenile Idiopathic Arthritis
|
|
Observational |
|
- Istituto Giannina Gaslini
- Members of the PRINTO network (PRINTO at www.printo.it)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Safety in patients with JIA on biologics/MTX from 3 to 10 years from drug initiation
- Long-term efficacy in patients with JIA on biologics/MTX from 3 to 10 years from drug initiation
- Predictors of safety from 3 to 10 years from drug initiation
- (and 5 more...)
|
9000 |
All |
6 Months to 30 Years (Child, Adult) |
NCT01399281 |
EU 260353 |
PharmaChild |
December 2011 |
December 2021 |
December 2021 |
July 21, 2011 |
March 5, 2018 |
|
- IRCCS G. Gaslini
Genoa, Italy
|
| 5 |
NCT03245801 |
Recruiting |
CAPRI National Juvenile Idiopathic Arthritis Registry |
- Juvenile Idiopathic Arthritis (JIA)
|
|
Observational |
|
- University of British Columbia
- Children's Hospital of Eastern Ontario
- The Hospital for Sick Children
- (and 11 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Proportion of Children with Clinical inactive disease
- Juvenile Arthritis Disease Activity Score
- Pain intensity
- (and 2 more...)
|
300 |
All |
up to 18 Years (Child, Adult) |
NCT03245801 |
H16-00309
UBC Number: F15-01938 |
|
February 1, 2017 |
February 1, 2026 |
February 1, 2026 |
August 10, 2017 |
August 10, 2017 |
|
- University of Calgary / Alberta Children's Hospital
Calgary, Alberta, Canada - University of Alberta
Edmonton, Alberta, Canada - BC Children's Hospital
Vancouver, British Columbia, Canada - (and 11 more...)
|
| 6 |
NCT03116763 |
Recruiting |
The iPeer2Peer Program for Adolescents With Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
- Behavioral: iPeer2Peer Mentorship
- Other: Active Comparator: Control Group
|
Interventional |
Not Applicable |
- The Hospital for Sick Children
- Provincial Health Services Authority
- IWK Health Centre
- Children's Hospital of Eastern Ontario
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- TRANSITION-Q (measuring change)
- PedsQL Arthritis Module (measuring change)
- PROMIS Pain Interference (measuring change)
- (and 12 more...)
|
262 |
All |
12 Years to 18 Years (Child, Adult) |
NCT03116763 |
1000054878 |
iPeer2Peer |
March 28, 2017 |
May 31, 2019 |
September 30, 2019 |
April 17, 2017 |
April 17, 2017 |
|
- BC Children's Hospital
Vancouver, British Columbia, Canada - The IWK Health Centre
Halifax, Nova Scotia, Canada - Children's Hospital of Eastern Ontario (CHEO)
Ottawa, Ontario, Canada - The Hospital for Sick Children
Toronto, Ontario, Canada
|
| 7 |
NCT03092427 |
Recruiting |
Probiotic Treatment in Juvenile Idiopathic Arthritis (JIA) |
- Juvenile Idiopathic Arthritis
|
- Dietary Supplement: VSL#3
- Other: Placebo
|
Interventional |
Not Applicable |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- To evaluate the impact of a regular intake of probiotic VSL#3 in addition to standard treatment in patients with JIA on the clinical activity
- To evaluate the impact of a regular intake of probiotic VSL#3 in addition to standard treatment in patients with JIA on the intestinal microbiota.
|
120 |
All |
1 Year to 7 Years (Child) |
NCT03092427 |
P150934 |
PERMAJI |
September 4, 2017 |
May 2019 |
May 2020 |
March 27, 2017 |
November 7, 2017 |
|
- Robert Debre Hospital
Paris, France
|
| 8 |
NCT03301883 |
Recruiting |
A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA) |
- Juvenile Idiopathic Arthritis
|
- Drug: Tocilizumab
- Drug: NSAIDs
- Drug: CSs
- Drug: MTX
|
Interventional |
Phase 4 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants Achieving Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 (JIA ACR30) Response With Absence of Fever, at Week 12
- Percentage of Participants Achieving JIA ACR30 Response With Absence of Fever, at Week 52
- Percentage of Participants With 30 Percent (%), 50%, 70%, and 90% Improvement From Baseline in JIA Core Set Parameters
- (and 11 more...)
|
65 |
All |
2 Years to 17 Years (Child) |
NCT03301883 |
YA39368 |
|
March 30, 2018 |
November 27, 2019 |
December 2, 2020 |
October 4, 2017 |
February 21, 2018 |
|
- Capital Institute of Pediatrics
Beijing City, China - Beijing Children's Hospital, Capital Medical University; rheumatism
Beijing City, China - Children's Hospital Chongqing Medical university
Chongqing, China
|
| 9 |
NCT02991469 |
Suspended |
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (sJIA) |
- Juvenile Idiopathic Arthritis
|
- Drug: Sarilumab SAR153191 (REGN88)
|
Interventional |
Phase 2 |
- Sanofi
- Regeneron Pharmaceuticals
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Assessment of PK parameter: maximum serum concentration observed (Cmax)
- Assessment of PK parameter: Area under the serum concentration versus time curve calculated using the trapezoidal method during a dose interval (AUC0-t)
- Assessment of PK parameter: Concentration observed before treatment administration during repeated dosing (Ctrough)
- (and 13 more...)
|
36 |
All |
1 Year to 17 Years (Child) |
NCT02991469 |
DRI13926
2015-004000-35
U1111-1177-3584 |
|
March 30, 2018 |
August 2023 |
August 2023 |
December 13, 2016 |
December 12, 2017 |
|
- Investigational Site Number 8400410
Akron, Ohio, United States - Investigational Site Number 0320060
Buenos Aires, Argentina - Investigational Site Number 0320004
San Miguel De Tucuman, Argentina - (and 31 more...)
|
| 10 |
NCT01469897 |
Completed |
Cost of Care for Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Direct and indirect costs
- Health related quality of life questionnaires
|
165 |
All |
Child, Adult, Senior |
NCT01469897 |
CCF 11-291 |
|
January 2012 |
December 2014 |
March 2017 |
November 10, 2011 |
January 17, 2018 |
|
- Children's Hospital & Medical Center
Omaha, Nebraska, United States - The Cleveland Clinic
Cleveland, Ohio, United States - Dell Childrens Medical Center of Central Texas
Austin, Texas, United States
|
| 11 |
NCT02776735 |
Recruiting |
An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) |
- Juvenile Idiopathic Arthritis
|
- Drug: Sarilumab SAR153191 (REGN88)
|
Interventional |
Phase 2 |
- Sanofi
- Regeneron Pharmaceuticals
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Assessment of PK parameter: maximum serum concentration observed (Cmax)
- Assessment of PK parameter: Area under the serum concentration versus time curve calculated using the trapezoidal method during a dose interval (AUC0-t)
- Assessment of PK parameter: Concentration observed before treatment administration during repeated dosing (Ctrough)
- (and 5 more...)
|
36 |
All |
2 Years to 17 Years (Child) |
NCT02776735 |
DRI13925
2015-003999-79
U1111-1177-3487 |
|
September 6, 2016 |
April 2018 |
April 25, 2022 |
May 18, 2016 |
April 12, 2018 |
|
- Investigational Site Number 8400413
Durham, North Carolina, United States - Investigational Site Number 8400410
Akron, Ohio, United States - Investigational Site Number 8400412
Cleveland, Ohio, United States - (and 38 more...)
|
| 12 |
NCT01436019 |
Unknown † |
Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
|
Observational |
|
- Blood Transfusion Centre of Slovenia
- University Medical Centre Ljubljana
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Determination of the presence and quantification of anti-drug antibodies by ELISA or other immunoassay.
- Determination of the presence and quantification of the serum level of the anti-TNF agent used for JIA therapy by ELISA or other immunoassay.
- Determination of the presence and quantification of the isotypes and subtypes of the anti-drug antibodies by ELISA or other immunoassay.
- Time to first detection of anti-drug antibodies.
|
100 |
All |
1 Year to 16 Years (Child) |
NCT01436019 |
BTC-PK-1 |
|
October 2011 |
October 2012 |
December 2012 |
September 19, 2011 |
September 19, 2011 |
|
- University Medical Centre
Ljubljana, Slovenia
|
| 13 |
NCT02024334 |
Unknown † |
Efficacy Study of Leflunomide to Treat Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Phase 4 |
- Mashhad University of Medical Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- thirty percent changes in the ACR Pediatric core set of disease activity measures in at least three of the six response variables (ACR Pedi 30)
- 50% and 70% changes in the ACR Pediatric core set of disease activity measures in at least three of the six response variables (ACR Pedi 30)
|
30 |
All |
2 Years to 19 Years (Child, Adult) |
NCT02024334 |
900527 |
JIA |
June 2013 |
June 2014 |
December 2014 |
December 31, 2013 |
December 31, 2013 |
|
- Mashhad, Khorasan Razavi, Iran, Islamic Republic of
|
| 14 |
NCT02196480 |
Completed |
23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Phase 4 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Seroprotection rate
- Seroconversion rate
- Number of participants with local and systemic adverse events
- Juvenile Arthritis Disease Activity Score with 27-joint reduced count (JADAS-27)
|
27 |
All |
5 Years to 18 Years (Child, Adult) |
NCT02196480 |
PPV23JIA-aTNF |
|
January 2008 |
June 2011 |
June 2012 |
July 22, 2014 |
July 22, 2014 |
|
- Centro de Dispensação de Medicamentos de Alto Custo (CEDMAC)
Sao Paulo, Brazil
|
| 15 |
NCT00775437 |
Completed
Has Results |
Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Phase 3 |
- AbbVie (prior sponsor, Abbott)
- AbbVie
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
- Mean Serum Adalimumab Trough Concentrations at Week 0, Week 12, and Week 24
- Hemoglobin: Mean Change From Baseline to Each Visit
- (and 44 more...)
|
32 |
All |
2 Years to 4 Years (Child) |
NCT00775437 |
M10-444
2009-013091-40 |
|
March 2009 |
March 2013 |
March 2013 |
October 20, 2008 |
January 26, 2016 |
January 26, 2016 |
|
| 16 |
NCT01986400 |
Completed |
Virtual Peer-to-Peer (VP2P) Support Mentoring for Juvenile Idiopathic Arthritis (JIA): A Pilot RCT |
- Juvenile Idiopathic Arthritis
|
- Behavioral: Virtual Peer-to-Peer Support Mentoring
|
Interventional |
Not Applicable |
- The Hospital for Sick Children
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Health Services Research
|
- Feasibility
- Health-Related Quality of Life (HRQL)
- Pain
- (and 3 more...)
|
30 |
All |
12 Years to 18 Years (Child, Adult) |
NCT01986400 |
1000038163 |
|
July 2013 |
May 2015 |
December 2016 |
November 18, 2013 |
January 3, 2018 |
|
- Hospital for Sick Children
Toronto, Ontario, Canada
|
| 17 |
NCT02165345 |
Active, not recruiting |
Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Juvenile Arthritis Disease Activity Score (JADAS-71)
- Percentage of Participants With Adverse Events (AEs), Serious AEs (AEs) and AEs of Special Interest
- Childhood Health Assessment Questionnaire (CHAQ) Score
- Percentage of Participants With Protocol Defined Inactive Disease/Clinical Remission
|
96 |
All |
2 Years to 18 Years (Child, Adult) |
NCT02165345 |
WA29231
2013-005212-98 |
|
July 16, 2014 |
November 6, 2020 |
November 6, 2020 |
June 17, 2014 |
January 12, 2018 |
|
- Arkansas Children's Hospital Research Institute
Little Rock, Arkansas, United States - University of Chicago Hospital
Chicago, Illinois, United States - Hackensack University Medical Center; Pediatric Rheumatology
Hackensack, New Jersey, United States - (and 28 more...)
|
| 18 |
NCT02052167 |
Completed |
Human Factors Study of Methotrexate Prefilled Pen (50 mg/mL) in Patients With Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
- Device: methotrexate prefilled pen
|
Interventional |
Early Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Device Feasibility
|
- Evaluation of test case scenarios with observation and performance measures
|
30 |
All |
2 Years to 20 Years (Child, Adult) |
NCT02052167 |
MC-MTX.16/HF Children |
|
April 2014 |
August 2014 |
August 2014 |
January 31, 2014 |
March 29, 2018 |
|
- Children's Mercy Hospital & Clinics
Kansas City, Missouri, United States
|
| 19 |
NCT00534495 |
Completed
Has Results |
Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Phase 2 |
- Montefiore Medical Center
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to Response to Treatment, as Determined by a Modified JIA ACR30 Requiring no Fever, Coupled With a Requirement for Corticosteroid Taper in Participants Who Are Taking Corticosteroids
- Number of Serious Adverse Events,Adverse Events, Infections, Development of MAS
- Number of Participants With Response as Determined by JIA ACR50 and JIA ACR70
- (and 3 more...)
|
71 |
All |
18 Months to 19 Years (Child, Adult) |
NCT00534495 |
N01 AR070015
268200700015C-2-0-0
HHSN2682007000015C |
|
November 2008 |
June 2013 |
June 2013 |
September 26, 2007 |
December 11, 2015 |
December 11, 2015 |
- Montefiore Medical Center
Bronx, New York, United States
|
| 20 |
NCT01904292 |
Completed |
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Tocilizumab
- Pharmacokinetics: Maximum Plasma Concentration (Cmax) of Tocilizumab
- Pharmacokinetics: Minimum Plasma Concentration (Cmin) of Tocilizumab
- (and 6 more...)
|
52 |
All |
1 Year to 17 Years (Child) |
NCT01904292 |
WA28118
2012-003490-26 |
|
August 15, 2013 |
June 13, 2017 |
June 13, 2017 |
July 22, 2013 |
November 20, 2017 |
|
- Arkansas Children's Hospital Research Institute
Little Rock, Arkansas, United States - Connecticut Children's Medical Center; 5E Clinical Trials Unit
Hartford, Connecticut, United States - Ann & Robert H. Lurie Children's Hospital of Chicago; Division of Rheumatology
Chicago, Illinois, United States - (and 39 more...)
|
| 21 |
NCT01904279 |
Completed
Has Results |
A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA) |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Minimum Serum Concentration (Cmin) of TCZ at Steady State
- Area Under the Curve at Steady-state Over a 12-week Interval (AUC12weeks) of TCZ Treatment
- Maximum Serum Concentration (Cmax) of TCZ at Steady State
- (and 5 more...)
|
52 |
All |
1 Year to 17 Years (Child) |
NCT01904279 |
WA28117
2012-003486-18 |
JIGSAW 117 |
July 2013 |
May 2016 |
May 2016 |
July 22, 2013 |
June 14, 2017 |
March 16, 2017 |
- Hartford, Connecticut, United States
- Chicago, Illinois, United States
- Chicago, Illinois, United States
- (and 32 more...)
|
| 22 |
NCT01230827 |
Terminated
Has Results |
A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS) |
- Juvenile Idiopathic Arthritis
|
- Drug: CNTO 148 (Golimumab)
- Drug: Placebo
- Drug: Methotrexate
|
Interventional |
Phase 3 |
- Janssen Research & Development, LLC
- Schering-Plough
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of Participants With American College of Rheumatology (ACR) 30 Response at Week 16 Who Did Not Experienced a Flare of Disease Through Week 48
- Percentage of Participants With American College of Rheumatology (ACR) 30 Response at Week 48
- Percentage of Participants With American College of Rheumatology (ACR) 30 Response Who Had Inactive Disease at Week 48
- Percentage of Participants Who Achieved Clinical Remission While on Medication for Juvenile Idiopathic Arthritis (JIA) at Week 48
|
173 |
All |
2 Years to 18 Years (Child, Adult) |
NCT01230827 |
CR017089
CNTO148JIA3001
2009-015019-42 |
|
December 2010 |
September 2013 |
May 2014 |
October 29, 2010 |
April 4, 2016 |
September 29, 2014 |
- Los Angeles, California, United States
- San Francisco, California, United States
- Augusta, Georgia, United States
- (and 32 more...)
|
| 23 |
NCT01541917 |
Completed
Has Results |
Efficacy of Web-based Pain Self-management for Adolescents With Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
- Behavioral: Web-based coping skills training
- Behavioral: Online disease education
|
Interventional |
Phase 3 |
- Children's Mercy Hospital Kansas City
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Pain Intensity
- Change in PedsQL Rheumatology Health-Related Quality of Life Total Score
- Change in Medical Issues, Exercise, Pain and Social Support Questionnaire (MEPS) Education Score
- (and 3 more...)
|
305 |
All |
12 Years to 18 Years (Child, Adult) |
NCT01541917 |
GRANT10829275
1R01AR061513-01 |
WebSMART |
July 2012 |
April 2016 |
June 2016 |
March 1, 2012 |
March 9, 2017 |
March 9, 2017 |
- University of California San Francisco Benioff Children's Hospital
San Francisco, California, United States - Lurie Children's Hospital
Chicago, Illinois, United States - Riley Hospital for Children
Indianopolis, Indiana, United States - (and 7 more...)
|
| 24 |
NCT01434082 |
Unknown † |
Sleep Patterns in Children With and Without Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
- Behavioral: comparison of types of sleep disordered breathing
|
Observational |
|
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Prevalence of Sleep Disordered Breathing
- Measures of Daytime Sleepiness
|
150 |
All |
6 Years to 11 Years (Child) |
NCT01434082 |
JIA
1R01NR012734-01 |
JIA |
September 2011 |
January 2015 |
February 2015 |
September 14, 2011 |
September 14, 2011 |
|
- University of Washington School of Nursing
Seattle, Washington, United States
|
| 25 |
NCT01500551 |
Recruiting |
Long-Term Safety Study Of Tofacinib In Patients With Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Standard laboratory safety data and adverse event (AE) reports. Body weight, height and Tanner Stages will collected to assess growth and physical development.
- Physician global evaluation of disease activity at each visit.
- Number of joints with active arthritis at each visit.
- (and 15 more...)
|
340 |
All |
2 Years to 18 Years (Child, Adult) |
NCT01500551 |
A3921145
2011-004915-22
JIA |
|
March 18, 2013 |
March 31, 2021 |
March 31, 2021 |
December 28, 2011 |
April 10, 2018 |
|
- Arkansas Children's Hospital- Attention: Jill Hernandez
Little Rock, Arkansas, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - Loma Linda University Children'S Hospital
Loma Linda, California, United States - (and 99 more...)
|
| 26 |
NCT01835470 |
Active, not recruiting
Has Results |
Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Phase 3 |
- Bristol-Myers Squibb
- Ono Pharmaceutical Co. Ltd
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants Experiencing a American College of Rheumatology (ACR) Pediatric 30 Response at Week 16
- Percentage of Participants Experiencing a American College of Rheumatology Pediatric 50, 70, 90 Response or Inactive Disease at Week 16
- Median Percentage of Improvement From Baseline in Physical Function as Assessed by the Childhood Health Assessment Questionnaire (CHAQ) Disability Index at Week 16
- (and 4 more...)
|
23 |
All |
4 Years to 17 Years (Child) |
NCT01835470 |
IM101-365 |
|
August 9, 2013 |
November 24, 2015 |
July 31, 2018 |
April 19, 2013 |
April 3, 2018 |
January 11, 2017 |
- Local Institution
Oobu-shi, Aichi, Japan - Local Institution
Sapporo-shi, Hokkaido, Japan - Local Institution
Sapporo-shi, Hokkaido, Japan - (and 10 more...)
|
| 27 |
NCT01727986 |
Completed |
An Extension Long-Term Study of RoActemra/Actemra (Tocilizumab) in Patients With Polyarticular Juvenile Idiopathic Arthritis Who Completed The WA19977 Study |
- Juvenile Idiopathic Arthritis
|
- Drug: tocilizumab [RoActemra/Actemra]
|
Interventional |
Phase 3 |
|
Industry |
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Long-term safety: Incidence of adverse events
- Response rates according to the American College of Rheumatology criteria for juvenile idiopathic arthritis (JIA ACR)
- Proportion of patients achieving inactive disease/clinical remission
|
11 |
All |
9 Years to 18 Years (Child, Adult) |
NCT01727986 |
ML28413 |
|
March 2013 |
November 2015 |
November 2015 |
November 16, 2012 |
May 5, 2016 |
|
- Rio de janeiro, RJ, Brazil
- Rio de Janeiro, RJ, Brazil
- Porto Alegre, RS, Brazil
- Sao Paulo, SP, Brazil
|
| 28 |
NCT01563185 |
Completed
Has Results |
Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
- Drug: 800 mg ibuprofen/26.6 mg famotidine
|
Interventional |
Phase 4 |
- Horizon Pharma Ireland, Ltd., Dublin Ireland
- Pediatric Rheumatology Collaborative Study Group
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)
- Childhood Health Questionnaire Parent Form 50 (CHQ-PF50) Scores
- American College of Rheumatology (ACR) Pediatric Core Measures: Physician's Global Assessment of Disease Activity and Parent's Assessment of Overall Well-being
- (and 8 more...)
|
12 |
All |
10 Years to 16 Years (Child) |
NCT01563185 |
HZ-CA-402 |
|
April 2012 |
March 2015 |
March 2015 |
March 26, 2012 |
December 23, 2015 |
December 23, 2015 |
- Children's Hospital
New Orleans, Louisiana, United States - Floating Hospital for Children @ Tufts Medical Center
Boston, Massachusetts, United States - UMASS Memorial Children's Medical Center
Worcester, Massachusetts, United States - (and 2 more...)
|
| 29 |
NCT01667471 |
Completed
Has Results |
A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study |
- Juvenile Idiopathic Arthritis
|
- Drug: tocilizumab [RoActemra/Actemra]
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Adverse Events of Special Interest and Study-Drug Related Adverse Events
- Number of AEs of Special Interest and Study Drug Related AEs
- Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30/50/70/90 by Visit
- (and 10 more...)
|
6 |
All |
9 Years to 18 Years (Child, Adult) |
NCT01667471 |
ML25756
2011-001097-25 |
|
January 2012 |
August 2013 |
August 2013 |
August 17, 2012 |
November 2, 2016 |
October 2, 2015 |
- Bremen, Germany
- Frankfurt/Main, Germany
- Sankt Augustin, Germany
|
| 30 |
NCT01557452 |
Terminated |
An Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic Arthritis (JIA) |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- long-term safety
- ACR pediatric 30 level of response
- ACR pediatric 50 and 70 levels of response
|
1 |
All |
2 Years to 18 Years (Child, Adult) |
NCT01557452 |
DSC/11/2357/42 |
|
December 2011 |
January 2014 |
January 2014 |
March 19, 2012 |
February 27, 2014 |
|
- 1st Faculty of Medicine and General Faculty Hospital
Praha, Czech Republic
|
| 31 |
NCT01673919 |
Completed
Has Results |
A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study |
- Juvenile Idiopathic Arthritis
|
- Drug: tocilizumab [RoActemra/Actemra]
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Any Adverse Events and Any Serious Adverse Events
- Number of Participants With Adverse Events of Special Interest
- Number of Participants With Adverse Events Related to Tocilizumab
- (and 16 more...)
|
7 |
All |
4 Years and older (Child, Adult, Senior) |
NCT01673919 |
ML28166
2011-005515-90 |
|
February 2012 |
January 2014 |
January 2014 |
August 28, 2012 |
November 2, 2016 |
November 2, 2016 |
- Le Kremlin Bicêtre, France
- Montpellier, France
- Paris, France
- Paris, France
|
| 32 |
NCT01676948 |
Withdrawn |
An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) |
- Systemic Juvenile Idiopathic Arthritis
|
- Drug: ACZ885
- Drug: Canakinumab
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- PRINTO / PRCSG
- Novartis
|
Industry / Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Long-term safety and tolerability of canakinumab and the retention rate of canakinumab-treated patients
- The percentage of patients who meet the adapted pediatric ACR, its individual components, and the Juvenile Arthritis Disease Activity Score [JADAS] over time
- The level of systemic corticosteroid tapering achieved in Part I
- (and 2 more...)
|
0 |
All |
2 Years to 20 Years (Child, Adult) |
NCT01676948 |
CACZ885G2402
2012-003054-92 |
β-SPECIFIC 4Pa |
January 2013 |
January 2015 |
January 2015 |
August 31, 2012 |
October 15, 2015 |
|
|
| 33 |
NCT01575769 |
Terminated
Has Results |
An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
- Drug: RoActemra/Actemra (tocilizumab)
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With Adverse Events (AEs)
- Percentage of Participants With JIA ACR 30 Response at Weeks 12, 24 and End of Follow Up
- Percentage of Participants With JIA ACR 50 Response at Weeks 12, 24 and End of Follow up
- (and 20 more...)
|
41 |
All |
2 Years and older (Child, Adult, Senior) |
NCT01575769 |
ML27783 |
|
January 19, 2012 |
December 3, 2013 |
December 3, 2013 |
April 11, 2012 |
February 9, 2018 |
January 7, 2016 |
- Wojewodzki Szpital Dzieciecy Im. J. Brudzinskiego
Bydgoszcz, Poland - Wojewodzki Specjalistyczny Szpital Dzieciecy Sw Ludwika; Oddzial Dzieci Starszych
Kraków, Poland - Uniwersytecki Szpital Kliniczny Nr 4 im. M. Konopnickiej; Oddz. Kardiolog. i Reumatolog. dla Dzieci
Lodz, Poland - (and 8 more...)
|
| 34 |
NCT01357668 |
Recruiting |
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Incidence rate of serious infections
- Incidence rate of malignancies
- Incidence rate of autoimmune disorders
- (and 2 more...)
|
900 |
All |
up to 17 Years (Child) |
NCT01357668 |
IM101-240 |
|
January 31, 2013 |
December 31, 2029 |
December 31, 2029 |
May 23, 2011 |
April 4, 2018 |
|
- Arkansas Children's Hospital
Little Rock, Arkansas, United States - Children's Hospital Los Angeles
Los Angeles, California, United States - Florida University
Gainesville, Florida, United States - (and 79 more...)
|
| 35 |
NCT01513902 |
Completed
Has Results |
Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA) |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Apparent Oral Clearance (CL/F)
- Number of Participants With Treatment-Emergent Adverse Events (AEs) All Causalities
- Number of Participants With Laboratory Test Abnormalities
- (and 7 more...)
|
26 |
All |
2 Years to 17 Years (Child) |
NCT01513902 |
A3921103
2011-004914-40 |
|
March 2013 |
December 2015 |
December 2015 |
January 20, 2012 |
July 4, 2016 |
July 4, 2016 |
- Explorer Clinic, University of Minnesota Children's Hospital
Minneapolis, Minnesota, United States - Clinical and Translational Science Institute Masonic Clinical Research Unit (Administration Only)
Minneapolis, Minnesota, United States - Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States - (and 7 more...)
|
| 36 |
NCT01287715 |
Unknown † |
Withdrawal of Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Phase 4 |
- Erasmus Medical Center
- Dutch Arthritis Association
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Flare-rate
- Duration of remission before withdrawal of etanercept
- Predictors for successful discontinuation of etanercept
- Disease course after flaring
|
50 |
All |
4 Years to 17 Years (Child) |
NCT01287715 |
NR 10-1-203 |
ABC-STOP |
January 2011 |
September 2012 |
September 2013 |
February 1, 2011 |
February 1, 2011 |
|
- Academic Medical Centre Emma Children's Hospital
Amsterdam, Netherlands - Reade Institute Amsterdam
Amsterdam, Netherlands - Sint-Lucas Andreas Hospital
Amsterdam, Netherlands - (and 7 more...)
|
| 37 |
NCT01455701 |
Completed |
A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA) |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Serum Concentration (Cmax) of Tocilizumab
- Minimum Serum Concentration (Cmin) of Tocilizumab
- Model predicted Area Under the Serum Concentration-Time Curve from Time Zero to End of Dosing (AUCtau) of Tocilizumab
- Number of Participants With Adverse Events (AEs) and Serious AEs
|
11 |
All |
up to 24 Months (Child) |
NCT01455701 |
NP25737
2015-000435-33 |
|
October 26, 2012 |
July 28, 2016 |
July 13, 2017 |
October 20, 2011 |
December 8, 2017 |
|
- Uni of California San Francisco
San Francisco, California, United States - Children's National Medical Center; Pediatric Rheumatology
Washington, District of Columbia, United States - The University of Chicago;Department of Pediatrics
Chicago, Illinois, United States - (and 26 more...)
|
| 38 |
NCT00836394 |
Completed |
Effect of Whole Body Vibration Therapy in Children With Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
- Device: Galileo (whole body vibration (WBV) therapy)
|
Interventional |
Not Applicable |
- Children's Hospital of Eastern Ontario
- Canadian Arthritis Network
- University of Ottawa
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- The primary objective is to evaluate the effect of whole body vibration therapy on muscle function by measuring the increase in z-score muscle power during a two leg jump as determined by jumping mechanography after 12 weeks compared to baseline.
- The increase in muscle force measured during a one leg jump as determined by jumping mechanography
- The increase in joint moment and power of the lower-limb measured in a gait lab using motion analysis
- (and 3 more...)
|
70 |
All |
7 Years to 18 Years (Child, Adult) |
NCT00836394 |
WBV-JIA |
WBV-JIA |
February 2009 |
January 2011 |
January 2011 |
February 4, 2009 |
June 28, 2011 |
|
- Children's Hospital of Eastern Ontario
Ottawa, Ontario, Canada
|
| 39 |
NCT01015547 |
Completed |
Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
- Drug: Infliximab plus methotrexate
- Drug: Combination of DMARDs
- Drug: Methotrexate alone
|
Interventional |
Phase 3 |
- Helsinki University Central Hospital
- Foundation for Paediatric Research, Finland
- Päivikki and Sakari Sohlberg Foundation, Finland
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- ACR Pedi 75 response
- clinically inactive disease
- time spent in inactive disease
- (and 5 more...)
|
60 |
All |
4 Years to 15 Years (Child) |
NCT01015547 |
211864, 318/E0/2002
211864 |
ACUTE-JIA |
May 2003 |
November 2007 |
December 2013 |
November 18, 2009 |
October 15, 2015 |
|
- Rheumatism Foundation Hospital
Heinola, Finland - Hospital for Children and Adolescents
Helsinki, Finland - Kuopio University Hospital
Kuopio, Finland - (and 3 more...)
|
| 40 |
NCT03006991 |
Recruiting |
Study of Methotrexate Given to Juvenile Idiopathic Arthritis Patients Based on Pharmacogenomics and Pharmacometrics |
- Juvenile Idiopathic Arthritis
|
- Other: therapeutic drug monitoring
|
Observational |
|
- Guangzhou Women and Children's Medical Center
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Genotypes as measured by polymerase chain reaction-restriction fragment length polymorphism
- Concentration as measured by liquid chromatography mass spectrometry
|
100 |
All |
1 Month to 18 Years (Child, Adult) |
NCT03006991 |
81603203 |
|
November 2016 |
December 2020 |
December 2023 |
December 30, 2016 |
December 30, 2016 |
|
- Guangzhou Women and Children's Medical Center
Guandong, Guangdong, China
|
| 41 |
NCT01803321 |
Completed |
Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA) |
- Systemic Juvenile Idiopathic Arthritis
|
- Drug: rilonacept (IL-1 Trap)
- Other: Placebo
|
Interventional |
Phase 1 |
- Regeneron Pharmaceuticals
|
Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Frequency of treatment emergent adverse events (TEAEs)
|
24 |
All |
4 Years to 20 Years (Child, Adult) |
NCT01803321 |
IL1T-AI-0504 |
|
November 2005 |
June 2008 |
June 2008 |
March 4, 2013 |
March 4, 2013 |
|
- Los Angeles, California, United States
- Wilmington, Delaware, United States
- Chicago, Illinois, United States
- (and 6 more...)
|
| 42 |
NCT00988221 |
Completed
Has Results |
A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
- Drug: Tocilizumab
- Drug: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percent of Patients With a Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology 30 (ACR30) Flare in Part II of the Study (Weeks 16-40)
- Percent of Patients Achieving Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology 30, 50, 70, and 90 (ACR30/50/70/90) Responses in Part I of the Study (Baseline to Week 16)
- Percent Change From Baseline in the Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) Component Score Physician Global Assessment of Disease Activity at the End of Part I of the Study (Week 16)
- (and 39 more...)
|
188 |
All |
2 Years to 17 Years (Child) |
NCT00988221 |
WA19977
2009-011593-15 |
|
November 30, 2009 |
November 30, 2011 |
January 28, 2013 |
October 2, 2009 |
July 26, 2017 |
November 1, 2012 |
- Connecticut Children's Medical Center; 5E Clinical Trials Unit
Hartford, Connecticut, United States - Children's National Medical Center; Pediatric Rheumatology
Washington, D.C., District of Columbia, United States - Delray Research Associates
Delray Beach, Florida, United States - (and 66 more...)
|
| 43 |
NCT00886769 |
Terminated
Has Results |
Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA) |
- Systemic Juvenile Idiopathic Arthritis
|
- Drug: Canakinumab
- Drug: Placebo
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
- Southwest Pediatric Nephrology Study Group
- Novartis
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of Patients Who Meet the Adapted American College of Rheumatology (ACR) Pediatric 30 Criteria
- Percentage of Patients Achieving the Adapted ACR Pediatric 50 Criteria
- Percentage of Patients Achieving the Adapted ACR Pediatric 70
- (and 7 more...)
|
84 |
All |
2 Years to 19 Years (Child, Adult) |
NCT00886769 |
CACZ885G2305
EudraCT: 2008-005476-27 |
β-SPECIFIC 1 |
July 2009 |
December 2010 |
January 2011 |
April 23, 2009 |
March 29, 2017 |
April 9, 2012 |
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Arkansas Children's Hospital Research Inst
Little Rock, Arkansas, United States - Children's Hospital Los Angeles
Los Angeles, California, United States - (and 88 more...)
|
| 44 |
NCT01603355 |
Terminated |
Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis |
- Juvenile Idiopathic Arthritis Associated Uveitis
|
|
Interventional |
Phase 1
Phase 2 |
- Eric B. Suhler
- Genentech, Inc.
- Oregon Health and Science University
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
3 |
All |
2 Years to 17 Years (Child) |
NCT01603355 |
e8343 |
|
November 2013 |
February 2016 |
February 2016 |
May 22, 2012 |
July 11, 2016 |
|
- Oregon Health & Science University
Portland, Oregon, United States
|
| 45 |
NCT00801593 |
Unknown † |
Magnetic Resonance Imaging Follow-up on Temporomandibular Arthritis in Children With Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
- Procedure: Steroid injection into the TMJs.
|
Observational |
|
- University Hospital Tuebingen
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- TMJ arthritis on MRI
- TMJ arthritis on ultrasound
- Action of current medication on TMJ arthritis.
|
50 |
All |
7 Years to 17 Years (Child) |
NCT00801593 |
TMJ PROSPECT2008 |
|
May 2008 |
December 2009 |
June 2010 |
December 3, 2008 |
December 3, 2008 |
|
- University Children's Hospital
Tuebingen, Baden-Wuerttemberg, Germany
|
| 46 |
NCT01544114 |
Completed
Has Results |
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA) |
- Juvenile Idiopathic Arthritis (JIA)
|
- Drug: VIMOVO 250/20
- Drug: VIMOVO 375/20
- Drug: VIMOVO 500/20
|
Interventional |
Phase 4 |
- Horizon Pharma Ireland, Ltd., Dublin Ireland
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and TEAEs Leading to Discontinuation (DC) of Study Drug
- Pharmacokinetics (PK) of Esomeprazole: Area Under the Concentration-Time Curve From the Time of Dosing to the Last Measurable Concentration (AUC[0-t])
- PK of Esomeprazole: Oral Plasma Clearance (CL/F)
- (and 3 more...)
|
46 |
All |
12 Years to 16 Years (Child) |
NCT01544114 |
D1120C00037 |
|
April 2012 |
February 2015 |
February 2015 |
March 5, 2012 |
October 4, 2017 |
October 4, 2017 |
- Research Site
Little Rock, Arkansas, United States - Research Site
San Francisco, California, United States - Research Site
Aurora, Colorado, United States - (and 14 more...)
|
| 47 |
NCT00891046 |
Completed
Has Results |
An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever. |
- Systemic Juvenile Idiopathic Arthritis
|
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Pediatric Rheumatology International Trials Organization
- Novartis
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs by Severity, AEs Leading to Discontinuation, SAEs Leading to Discontinuation, Treatment Related AEs and SAE
- Number of Participants With Anti -ACZ885 Antibodies at Any Visit During the Study
- Number of Participants With Clinically Significant Local Injection Site Reactions During the Study
- (and 16 more...)
|
270 |
All |
2 Years to 19 Years (Child, Adult) |
NCT00891046 |
CACZ885G2301E1
EudraCT: 2008-008008-42 |
β-SPECIFIC 3 |
September 2009 |
December 2014 |
December 2014 |
April 30, 2009 |
March 10, 2017 |
March 10, 2017 |
- Novartis Investigative Site
Los Angeles, California, United States - Novartis Investigative Site
Louisville, Kentucky, United States - Novartis Investigative Site
Boston, Massachusetts, United States - (and 70 more...)
|
| 48 |
NCT00642460 |
Completed
Has Results |
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA) |
- Juvenile Idiopathic Arthritis
|
- Drug: tocilizumab [RoActemra/Actemra]
- Drug: Placebo
- Drug: Non-steroidal anti-inflammatory drugs (NSAIDs)
- (and 2 more...)
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Part I: Percentage of Participants With ≥30% Improvement in Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) Core Set and Absence of Fever
- Part II: Percentage of Participants With Decreases in Oral Corticosteroid Dose at Week 104
- Part I: Percentage of Participants With JIA Core Set ACR 30/50/70/90 Response at Week 12
- (and 32 more...)
|
112 |
All |
2 Years to 17 Years (Child) |
NCT00642460 |
WA18221
2007-000872-18 |
|
May 2008 |
September 2009 |
August 2014 |
March 25, 2008 |
July 25, 2016 |
October 26, 2011 |
- Little Rock, Arkansas, United States
- Los Angeles, California, United States
- Hartford, Connecticut, United States
- (and 51 more...)
|
| 49 |
NCT01844518 |
Active, not recruiting
Has Results |
Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) |
- Active Polyarticular Juvenile Idiopathic Arthritis
|
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Abatacept Trough Concentration (Cmin) in Participants Ages 6 to 17
- Percentage of Participants (Ages 6 to 17) Achieving American College of Rheumatology Pediatric 30 Response (ACRp30)
- Number of Participants (Ages 6 to 17) With Adverse Events (AEs), Deaths, Serious AEs (SAEs) and AEs Leading to Discontinuation in the Short Term Period
- (and 5 more...)
|
187 |
All |
2 Years to 17 Years (Child) |
NCT01844518 |
IM101-301
2012-003195-39 |
|
June 28, 2013 |
March 12, 2015 |
December 29, 2023 |
May 1, 2013 |
February 15, 2018 |
March 24, 2016 |
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Arkansas Children's Hosptial
Little Rock, Arkansas, United States - Connecticut Children's Medical Center
Hartford, Connecticut, United States - (and 52 more...)
|
| 50 |
NCT01734382 |
Recruiting |
A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab) |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with fever (attributable to sJIA) in part 2 of the study
- Number of participants with adverse events
- Juvenile arthritis disease activity score (JADAS-71) at the end of Part 2 of the study
- (and 11 more...)
|
65 |
All |
2 Years to 17 Years (Child) |
NCT01734382 |
WA28029
2012-000444-10 |
|
June 10, 2013 |
September 7, 2019 |
September 7, 2019 |
November 27, 2012 |
January 12, 2018 |
|
- Children's Hospital Los Angeles; Division of Rheumatoogy
Los Angeles, California, United States - Cincinnati Children'S Hospital Medical Center; Division of Rheumatology
Cincinnati, Ohio, United States - Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States - (and 27 more...)
|
Create an RSS feed from your search for:
Download the search results for: